- Open Access
Assessment of mitral bioprostheses using cardiovascular magnetic resonance
Journal of Cardiovascular Magnetic Resonance volume 12, Article number: 36 (2010)
The orifice area of mitral bioprostheses provides important information regarding their hemodynamic performance. It is usually calculated by transthoracic echocardiography (TTE), however, accurate and reproducible determination may be challenging. Cardiovascular magnetic resonance (CMR) has been proven as an accurate alternative for assessing aortic bioprostheses. However, whether CMR can be similarly applied for bioprostheses in the mitral position, particularly in the presence of frequently coincident arrhythmias, is unclear. The aim of the study is to test the feasibility of CMR to evaluate the orifice area of mitral bioprostheses.
CMR planimetry was performed in 18 consecutive patients with mitral bioprostheses (n = 13 Hancock®, n = 4 Labcore®, n = 1 Perimount®; mean time since implantation 4.5 ± 3.9 years) in an imaging plane perpendicular to the transprosthetic flow using steady-state free-precession cine imaging under breath-hold conditions on a 1.5T MR system. CMR results were compared with pressure half-time derived orifice areas obtained by TTE.
Six subjects were in sinus rhythm, 11 in atrial fibrillation, and 1 exhibited frequent ventricular extrasystoles. CMR image quality was rated as good in 10, moderate in 6, and significantly impaired in 2 subjects. In one prosthetic type (Perimount®), strong stent artifacts occurred. Orifice areas by CMR (mean 2.1 ± 0.3 cm2) and TTE (mean 2.1 ± 0.3 cm2) correlated significantly (r = 0.94; p < 0.001). Bland-Altman analysis showed a 95% confidence interval from -0.16 to 0.28 cm2 (mean difference 0.06 ± 0.11 cm2; range -0.1 to 0.3 cm2). Intra- and inter-observer variabilities of CMR planimetry were 4.5 ± 2.9% and 7.9 ± 5.2%.
The assessment of mitral bioprostheses using CMR is feasible even in those with arrhythmias, providing orifice areas with close agreement to echocardiography and low observer dependency. Larger samples with a greater variety of prosthetic types and more cases of prosthetic dysfunction are required to confirm these preliminary results.
The hemodynamic evaluation of heart valve bioprostheses is based on a comprehensive assessment of transprosthetic pressure gradients and orifice area, preferably by using transthoracic echocardiography (TTE) . However, TTE is frequently limited due to restricted acoustic windows following cardiac surgery and due to methodical concerns . In particular, the assessment of the prosthetic orifice area, which is the main parameter used to differentiate between a normal functioning prosthesis, prosthetic stenosis and patient-prosthesis mismatch, often remains a challenge.
Recently, cardiovascular magnetic resonance (CMR) has been identified as an accurate non-invasive tool for the assessment of the orifice area of bioprostheses implanted in the aortic position. The orifice areas obtained by CMR planimetry agreed well with those obtained by TTE and transesophageal echocardiography, and artifacts caused by flow turbulences and prosthetic material were rare .
Based on these experiences with aortic bioprostheses, and on the established application of CMR to assess the severity of native mitral stenosis [4, 5], it would be desirable to apply this method to bioprostheses implanted in the mitral position. However, whether CMR can be applied to mitral bioprostheses is unclear, particularly due to the frequent coincidence of arrhythmias. Therefore, the aim of this study was to determine the feasibility of CMR to quantify the orifice area of mitral bioprostheses and compare the results to TTE.
The inclusion criterion for entry into the study was the presence of a biological mitral prosthesis; exclusion criteria were general contraindications for CMR . Screening the database of all patients who underwent echocardiography at our hospital between 2007 and 2009, we identified 138 patients who had undergone mitral valve replacement. Eighteen patients were eligible for the study. Their characteristics and distribution of valve types are depicted in Table 1. One hundred and twenty patients did not meet the inclusion criteria, since (possible nomination of ≥1 reason in each subject) the mitral prosthesis was a mechanical device (n = 74), due to the presence of a pacemaker (n = 29) or internal converter defibrillator (n = 8), because they refused to participate (n = 13) or had claustrophobia (n = 3). The study was carried out in compliance with the Declaration of Helsinki, the institutional ethics committee approved the study (EA3/015/07), and all patients gave written informed consent.
TTE was performed on state-of-the-art ultrasound systems (General Electric Healthcare, Vivid 7, Waukesha, USA; Philips Medical Systems, IE33, Andover, USA) in accordance with international guidelines [1, 7]. In the presence of arrhythmia, each measurement was repeated at least five times and a mean result was calculated. Peak and mean transprosthetic pressure gradients were obtained using the modified Bernoulli equation. Prosthetic orifice area was calculated based on the pressure half time .
Cardiovascular magnetic resonance
All patients underwent CMR in a clinical 1.5-Tesla MR scanner (Magnetom Avanto, Siemens Healthcare, Erlangen, Germany). For prosthetic orifice visualization, steady-state free-precession (SSFP) cine images were acquired during expiratory breath-holds and with retrospective electrocardiographic gating. Imaging parameters were: slice thickness 5 mm; no gap; repetition time 2.9 ms; echo time 1.2 ms; flip angle 80°; field of view 340 to 380 mm2; matrix 256 × 146; bandwidth 930 Hz/px; 30 phases per R-R-interval. In a subgroup of 13 patients, prosthetic orifice was additionally depicted using fast gradient echo (FGRE) cine loops. Imaging parameters were: slice thickness 5 mm, no gap, repetition time 6.5 ms, echo time 3.1 ms; flip angle 15°; field of view 340 to 380 mm2, matrix 192 × 125, bandwidth 260 Hz/px, 25 phases per R-R interval.
Positioning of the cine loops for orifice planimetry was performed in a stepwise fashion to ensure accurate positioning of the imaging plane perpendicular to the transprosthetic jet (Figure 1): Based on the four- or three-chamber-view, two subsequent planes were positioned centrally through the transprosthetic jet. Then, a stack of about six slices perpendicular to the jet was planned. Planimetry of the diastolic orifice area was performed in a single frame based on cross-references using the software CMR42 (CIRCLE Cardiovascular Imaging, Calgary, Alberta, Canada).
Images were rated regarding overall image quality on a scale from 0 to 3 (0 poor, non-diagnostic; 1 impaired image quality that may lead to misdiagnosis; 2 moderate; 3 good). To test intra-observer variability of CMR planimetry, one investigator (FvK) analyzed all examinations twice with a latency of at least three months. To test inter-observer variability, two independent observers (FvK; AR), who were unaware of each other's interpretations, performed planimetry.
Examination of ventricular function was performed by acquisition of SSFP cine images in standard four- and two-chamber views, and where wall motion abnormalities were present, in a stack of short axes covering the whole left ventricle (imaging parameters as described elsewhere ).
Results are presented as mean ± standard deviation. Correlations between orifice areas obtained by TTE and CMR were analyzed using the Spearman rank order correlation test and are displayed as scattergrams with regression line. Bland-Altman analysis was used to evaluate the agreement between orifice area measurements according to the various methods, and to determine observer-related variability. Statistical significance was implied where p < 0.05. Statistical analyses were performed using Prism 5.0 (Graphpad Software, La Jolla, CA, USA).
Echocardiographic assessment of mitral bioprostheses
Peak and mean transprosthetic pressure gradients were 11.5 ± 4.9 mmHg (range 6-22 mmHg) and 4.6 ± 2.5 mmHg (range 2-11 mmHg). Mean pressure half time was 110.8 ± 26.9 ms (range 85-192 ms). Mean prosthetic orifice area was 2.1 ± 0.3 cm2 (range 1.5-2.6 cm2). Prosthetic regurgitation was present in 16 subjects (15 mild, 1 severe). Aortic and tricuspid regurgitation were present in 16 (13 mild, 3 moderate) and 18 (10 mild, 8 moderate) subjects. There was no patient without any left-sided valvular regurgitation. Five subjects had concomitant biological aortic valve replacement.
Feasibility of CMR to image the mitral bioprosthesis
The image quality was rated as "good" in 10 (Figure 2, Additional file 1), "moderate" in 6 and "impaired that may lead to misdiagnosis" in 2 subjects. The reason for the significantly impaired image quality in 2 patients were considerable artifacts caused by the prosthetic stent in one subject (Figure 2, Additional file 2), and artifacts caused by mal-triggering in atrial fibrillation and insufficient breath holding in the other. The image quality rating differed significantly between evaluations in the presence and absence of arrhythmias (2.2 vs. 3.0; p = 0.013). All subjects in sinus rhythm had "good" image quality, and all subjects with "moderate" or "impaired" image quality had arrhythmias. On the other hand, even 4 subjects with atrial fibrillation achieved "good" image quality. In five subjects, an impaired opening movement of at least one valvular cusp was detected by CMR (Additional file 3).
Additional file 1: Mitral bioprosthesis imaged by SSFP. SSFP cine movie of a mitral bioprosthesis representing good image quality (Labcore® #27, implanted 2005, in sinus rhythm). (MOV 957 KB)
Additional file 2: Stent artifact. SSFP cine movie of a mitral bioprosthesis with markedly impaired image quality due to artifacts caused by stent material (Perimount® #31, implanted 2001, in atrial fibrillation). (MOV 1 MB)
Additional file 3: Prosthetic dysfunction. SSFP cine movie of a mitral bioprosthesis with structural deterioration leading to incomplete diastolic opening of the valvular cusps (Hancock® #33, implanted 2000, in atrial fibrillation). (MOV 975 KB)
Accuracy of quantification of the mitral prosthetic orifice area by CMR
Mean prosthetic orifice area obtained by CMR was 2.1 ± 0.3 cm2 (n = 18; range 1.5 to 2.7 cm2). Correlation analysis with TTE was significant (r = 0.94; p < 0.001) (Figure 3). Bland-Altman analysis revealed a 95% confidence interval ranging from -0.16 to 0.28 cm2 when comparing TTE- and CMR-derived orifice areas (mean difference 0.06 ± 0.11 cm2, range -0.1 to 0.3 cm2) (Figure 3).
Bland-Altman analysis of TTE- and CMR-derived orifice areas in dependence of the heart rhythm revealed a 95% confidence interval from -0.27 to 0.20 cm2 (mean difference -0.03 ± 0.12 cm2, range -0.2 to 0.1 cm2) in subjects with sinus rhythm (n = 6), and from -0.28 to 0.13 cm2 (mean difference -0.08 ± 0.11 cm2, range -0.3 to 0.1 cm2) in subjects with arrhythmias (n = 12). Bland-Altman analysis of TTE- and CMR-derived orifice areas referring to image quality showed a 95% confidence interval from -0.20 cm2 to 0.18 cm2 (mean difference -0.01 ± 0.10 cm2, range -0.2 to 0.1 cm2) in "good" image quality (n = 10), and from -0.30 to 0.05 cm2 (mean difference -0.13 ± 0.09 cm2; range -0.3 to 0.0 cm2) in "moderate" and "impaired" image quality (n = 8).
Agreement between both methods was similar for orifice areas smaller than the median 2.1 cm2 (n = 8; 95% confidence interval -0.17 to 0.27 cm2; mean difference 0.05 ± 0.11 cm2) and ≥2.1 cm2 (n = 10; 95% confidence interval -0.17 to 0.31 cm2; mean difference 0.07 ± 0.12 cm2).
Regarding the application of FGRE for planimetry, Bland-Altman analysis revealed a 95% confidence interval ranging from -0.37 to 0.31 cm2 when comparing SSFP and FGRE (mean difference -0.03 ± 0.17 cm2; range -0.3 to 0.3 cm2) and from -0.29 to 0.35 cm2 when comparing FGRE and TTE (mean difference 0.03 ± 0.16 cm2; range -0.2 to 0.4 cm2). Figure 4 shows a mitral bioprosthesis imaged by FGRE and SSFP (Additional file 4).
Additional file 4: Mitral bioprosthesis imaged by FGRE. FGRE cine movie of a mitral bioprosthesis (Hancock® #31, implanted 2008, in sinus rhythm). (MOV 876 KB)
Intra- and inter-observer variability of CMR planimetry
Repeated measurements of prosthetic orifice area by CMR-planimetry by one investigator resulted in an intra-observer variability of 4.5 ± 2.9% (range 0 to 9.5%). Bland-Altman analysis revealed a mean difference of 0.03 ± 0.11 cm2 (range -0.2 to 0.2 cm2; 95% confidence interval -0.19 to 0.25 cm2). Assessment by two blinded observers revealed an inter-observer variability of 7.9 ± 5.2% (0.0 to 21.1%). Bland-Altman analysis revealed a mean difference of -0.08 ± 0.19 cm2 (range -0.4 to 0.2 cm2; 95% confidence interval -0.30 to 0.46 cm2).
Planimetry is the most direct, and thus should be the most stable approach to determine a valvular orifice area. It is not derived from other hemodynamic and geometric calculations and hence is widely independent from hemodynamic conditions. For mitral valves, planimetry showed the best correlation with anatomical mitral valve area as assessed on explanted valves  and is therefore considered as the reference measurement of mitral valve area . Based on the successful application of CMR planimetry in aortic bioprostheses, we hypothesized that CMR planimetry of mitral bioprostheses would also provide accurate orifice areas, as long as the image quality allows for a clear-cut delineation of the prosthetic cusp borders.
Feasibility of CMR to image mitral bioprostheses
We have demonstrated the feasibility of CMR to image mitral bioprostheses, even in the presence of arrhythmias. Indeed, only 6 subjects presented in sinus rhythm, while 1 had frequent ventricular extrasystoles and 11 were experiencing atrial fibrillation. This incidence of arrhythmia is typical for patients previously suffering from mitral regurgitation or stenosis and having atrial dilatation . As SSFP cine movies collect data over several cardiac cycles, the image quality negatively correlates with the extent of arrhythmia and with increasing heart rate. Even in the present sample, differences in image quality were observed between patients in sinus rhythm and those with arrhythmia. Nevertheless, none of the examinations hat to be excluded due to non-diagnostic image quality. But, optimal heart rate control is recommended preceding the assessment of a mitral bioprosthesis by CMR.
A strong stent artifact appeared in one subject with a Perimount® prosthesis, whereas this phenomenon did not occur in the remaining subjects, who received other types of devices. This underlines that some prostheses are less suitable for CMR assessment and that the type of the valve makes an important difference concerning image quality. The differences probably depend on the shape and quantity of metal within the stent, and on its composition, which is a cobalt-chromium spring alloy in the Perimount®. Further trials including a greater variety of prosthetic types are warranted.
Artifacts caused by turbulent flow did not constitute a significant challenge in mitral prostheses, which can be attributed to the low transmitral blood flow velocity. Therefore, SSFP is the sequence of choice despite its general susceptibility for turbulent flow [12, 13]. In rare cases with flow artifacts, less flow sensitive FGRE  may be applied. However, mitral prosthetic orifice areas obtained by FGRE showed less agreement with TTE than those determined by SSFP, which is in accordance with the use of FGRE to evaluate aortic stenosis .
Accuracy of CMR to quantify the orifice area of mitral bioprostheses
Direct comparison of the orifice areas obtained by CMR planimetry with a gold standard would be desirable to confirm our hypothesis that CMR of mitral bioprostheses provides accurate prosthetic orifice areas. However, a true gold standard does not exist. Even when evaluating native mitral stenosis it is recommended that calculated mitral valve area by any one method should not be used as the single measure of severity of stenosis . Orifice areas provided by the manufacturers are not a suitable gold standard, as they mostly comprise the geometric orifice area in-vitro, which is different from the orifice area effectively used in-vivo . Planimetry using echocardiography is complicated by difficulties in identifying the correct cross-section [17, 18]. Three-dimensional imaging may improve echocardiography [19, 20], but has not yet entered routine clinical practice. The accuracy and reproducibility of the continuity equation are hampered by the number of contributing measurements, which is even more problematic in arrhythmias . Furthermore, this algorithm is inappropriate in those with aortic or mitral regurgitation, as in our study subjects. The validity of pressure half time derived orifice areas, as traditionally applied in native mitral stenosis , is unclear in prosthetic valves, because of the dependence on left ventricular and left atrial compliance, on left atrial pressure and heart rate [1, 21–23]. Nevertheless, in the absence of a better standard, and bearing these limitations in mind, we selected this parameter as the most appropriate for our study.
CMR planimetry of mitral bioprosthetic orifice area was significantly correlated with data obtained by TTE. The agreement between both methods was similar to the successful application of CMR to assess native mitral valve stenosis by Djavidani et al. (r = 0.98; mean difference 0.03 ± 0.09 cm2)  and even superior compared to another series by this group (r = 0.81; mean difference 0.13 ± 0.24 cm2) . Compared to the application of computed tomography to assess native mitral valves in comparison to TTE-planimetry (r = 0.88; mean difference 0.20 ± 0.17 cm2) , the present results in mitral bioprostheses showed even closer agreement. In comparison to our results of CMR and TTE to assess aortic bioprostheses (r = 0.82; mean difference -0.02 ± 0.24 cm2) , the limits of agreement of CMR and TTE in mitral prosthetic assessment were smaller.
The present results demonstrated similar agreement between CMR- and TTE- derived orifice areas both in the presence or absence of arrhythmias. There was a tendency towards underestimation of orifice areas using CMR compared to TTE in examinations rated with "moderate" and "impaired" image quality, which may be explained by less accurate delineation of the border between blood and prosthetic cusps. However, the sample size is too small to draw firm conclusions regarding the influence of arrhythmias and image quality on prosthetic orifice assessment; thus, larger series are required.
CMR and TTE showed agreement that was independent of prosthetic orifice area. However, the study sample only contained 3 patients with an orifice area ≤1.7 cm2 and just 1 patient with an orifice area ≤1.5 cm2. Prosthetic dysfunction may be associated with increased turbulent flow causing significant flow artifacts, which may influence image interpretation. Therefore, larger clinical trials are required to extend the use of CMR to the assessment of dysfunctional mitral prostheses.
The inter- and intra-observer variabilities of CMR planimetry were low and within the range of accepted echocardiographic results that report 5% to 8% variability for experienced observers examining native aortic valves . Observer dependency was also comparable to data obtained using CMR in aortic bioprostheses with an intra- and interobserver variablity of 6.7% and 11.5%, respectively .
Clinical impact of CMR to quantify the orifice area of mitral bioprostheses
TTE will remain the first choice for the assessment of mitral bioprostheses due to its ready availability, even bedside in the intensive care, cost effectiveness, non-invasiveness and proven accuracy. Bioprosthetic mitral valves constitute a very small number of patients undergoing mitral valve surgery, and of those an even smaller percentage will have unfavorable acoustic windows making Doppler interrogation unreliable. Nevertheless the present results demonstrated that for selected subjects, e.g. in case of insufficient acoustic windows, discordant echocardiographic results or within clinical research regarding patient-prosthesis mismatch , CMR planimetry poses a reliable non-invasive method to quantify the prosthetic orifice area.
We demonstrated the feasibility of CMR to image mitral bioprostheses and to accurately assess the orifice area with close agreement to echocardiography and low observer dependency. Even though image quality decreased with the presence of arrhythmias and seemed to depend on the prosthetic type, all CMR examinations provided diagnostic image quality. Further clinical studies including patients with prosthetic dysfunction and a greater variety of prosthetic types are necessary to fully elucidate the applicability of these findings to a wider population.
Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS, Grayburn PA, Khandheria BK, Levine RA, Marx GR, Miller FA, Nakatani S, Quiñones MA, Rakowski H, Rodriguez LL, Swaminathan M, Waggoner AD, Weissman NJ, Zabalgoitia M, American Society of Echocardiography's Guidelines and Standards Committee; Task Force on Prosthetic Valves; American College of Cardiology Cardiovascular Imaging Committee; Cardiac Imaging Committee of the American Heart Association; European Association of Echocardiography; European Society of Cardiology; Japanese Society of Echocardiography; Canadian Society of Echocardiography; American College of Cardiology Foundation; American Heart Association; European Association of Echocardiography; European Society of Cardiology; Japanese Society of Echocardiography; Canadian Society of Echocardiography : Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2009, 22: 975-1014. 10.1016/j.echo.2009.07.013. quiz 1082-1014
Pflederer T, Flachskampf FA: Echocardiographic follow-up after heart valve replacement. Heart (British Cardiac Society). 96: 75-85.
von Knobelsdorff-Brenkenhoff F, Rudolph A, Wassmuth R, Bohl S, Buschmann EE, Abdel-Aty H, Dietz R, Schulz-Menger J: Feasibility of cardiovascular magnetic resonance to assess the orifice area of aortic bioprostheses. Circ Cardiovasc Imaging. 2009, 2: 397-404. 10.1161/CIRCIMAGING.108.840967. 392 p following 404
Djavidani B, Debl K, Lenhart M, Seitz J, Paetzel C, Schmid FX, Nitz WR, Feuerbach S, Riegger G, Luchner A: Planimetry of mitral valve stenosis by magnetic resonance imaging. Journal of the American College of Cardiology. 2005, 45: 2048-2053. 10.1016/j.jacc.2005.03.036.
Lin SJ, Brown PA, Watkins MP, Williams TA, Lehr KA, Liu W, Lanza GM, Wickline SA, Caruthers SD: Quantification of stenotic mitral valve area with magnetic resonance imaging and comparison with Doppler ultrasound. Journal of the American College of Cardiology. 2004, 44: 133-137. 10.1016/j.jacc.2004.03.038.
Dill T: Contraindications to magnetic resonance imaging: non-invasive imaging. Heart (British Cardiac Society). 2008, 94: 943-948.
Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, Iung B, Otto CM, Pellikka PA, Quinones M: Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009, 22: 1-23. 10.1016/j.echo.2008.11.029. quiz 101-102
Hatle L, Angelsen B, Tromsdal A: Noninvasive assessment of atrioventricular pressure half-time by Doppler ultrasound. Circulation. 1979, 60: 1096-1104.
Faletra F, Pezzano A, Fusco R, Mantero A, Corno R, Crivellaro W, De Chiara F, Vitali E, Gordini V, Magnani P, Pezzano A: Measurement of mitral valve area in mitral stenosis: four echocardiographic methods compared with direct measurement of anatomic orifices. Journal of the American College of Cardiology. 1996, 28: 1190-1197. 10.1016/S0735-1097(96)00326-9.
Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology. 2008, 52: e1-142. 10.1016/j.jacc.2008.05.007.
Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL, American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society: ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006, 114: e257-354. 10.1161/CIRCULATIONAHA.106.177292.
Friedrich M, Schulz-Menger J, Dietz R: Magnetic resonance to assess the aortic valve area in aortic stenosis. Journal of the American College of Cardiology. 2004, 43: 2148-10.1016/j.jacc.2004.03.010. author reply 2148-2149
Hildebrand LB, Buonocore MH: Fully refocused gradient recalled echo (FRGRE): factors affecting flow and motion sensitivity in cardiac MRI. J Cardiovasc Magn Reson. 2002, 4: 211-222. 10.1081/JCMR-120003947.
Schlosser T, Malyar N, Jochims M, Breuckmann F, Hunold P, Bruder O, Erbel R, Barkhausen J: Quantification of aortic valve stenosis in MRI-comparison of steady-state free precession and fast low-angle shot sequences. European radiology. 2007, 17: 1284-1290. 10.1007/s00330-006-0437-5.
Klarich KW, Rihal CS, Nishimura RA: Variability between methods of calculating mitral valve area: simultaneous Doppler echocardiographic and cardiac catheterization studies conducted before and after percutaneous mitral valvuloplasty. J Am Soc Echocardiogr. 1996, 9: 684-690. 10.1016/S0894-7317(96)90065-6.
Bleiziffer S, Eichinger WB, Hettich I, Guenzinger R, Ruzicka D, Bauernschmitt R, Lange R: Prediction of valve prosthesis-patient mismatch prior to aortic valve replacement: which is the best method?. Heart (British Cardiac Society). 2007, 93: 615-620.
Binder TM, Rosenhek R, Porenta G, Maurer G, Baumgartner H: Improved assessment of mitral valve stenosis by volumetric real-time three-dimensional echocardiography. Journal of the American College of Cardiology. 2000, 36: 1355-1361. 10.1016/S0735-1097(00)00852-4.
Messika-Zeitoun D, Iung B, Brochet E, Himbert D, Serfaty JM, Laissy JP, Vahanian A: Evaluation of mitral stenosis in 2008. Archives of cardiovascular diseases. 2008, 101: 653-663. 10.1016/j.acvd.2008.06.016.
Zamorano J, Cordeiro P, Sugeng L, Perez de Isla L, Weinert L, Macaya C, Rodriguez E, Lang RM: Real-time three-dimensional echocardiography for rheumatic mitral valve stenosis evaluation: an accurate and novel approach. Journal of the American College of Cardiology. 2004, 43: 2091-2096. 10.1016/j.jacc.2004.01.046.
Perez de Isla L, Casanova C, Almeria C, Rodrigo JL, Cordeiro P, Mataix L, Aubele AL, Lang R, Zamorano JL: Which method should be the reference method to evaluate the severity of rheumatic mitral stenosis? Gorlin's method versus 3D-echo. Eur J Echocardiogr. 2007, 8: 470-473. 10.1016/j.euje.2006.08.008.
Nakatani S, Masuyama T, Kodama K, Kitabatake A, Fujii K, Kamada T: Value and limitations of Doppler echocardiography in the quantification of stenotic mitral valve area: comparison of the pressure half-time and the continuity equation methods. Circulation. 1988, 77: 78-85.
Dumesnil JG, Honos GN, Lemieux M, Beauchemin J: Validation and applications of mitral prosthetic valvular areas calculated by Doppler echocardiography. The American journal of cardiology. 1990, 65: 1443-1448. 10.1016/0002-9149(90)91352-7.
Kim HK, Kim YJ, Chang SA, Kim DH, Sohn DW, Oh BH, Park YB: Impact of cardiac rhythm on mitral valve area calculated by the pressure half time method in patients with moderate or severe mitral stenosis. J Am Soc Echocardiogr. 2009, 22: 42-47. 10.1016/j.echo.2008.11.007.
Djavidani B, Debl K, Buchner S, Lipke C, Nitz W, Feuerbach S, Riegger G, Luchner A: MRI planimetry for diagnosis and follow-up of valve area in mitral stenosis treated with valvuloplasty. Rofo. 2006, 178: 781-786.
Messika-Zeitoun D, Serfaty JM, Laissy JP, Berhili M, Brochet E, Iung B, Vahanian A: Assessment of the mitral valve area in patients with mitral stenosis by multislice computed tomography. Journal of the American College of Cardiology. 2006, 48: 411-413. 10.1016/j.jacc.2006.04.035.
Goland S, Trento A, Iida K, Czer LS, De Robertis M, Naqvi TZ, Tolstrup K, Akima T, Luo H, Siegel RJ: Assessment of aortic stenosis by three-dimensional echocardiography: an accurate and novel approach. Heart (British Cardiac Society). 2007, 93: 801-807.
Magne J, Mathieu P, Dumesnil JG, Tanne D, Dagenais F, Doyle D, Pibarot P: Impact of prosthesis-patient mismatch on survival after mitral valve replacement. Circulation. 2007, 115: 1417-1425. 10.1161/CIRCULATIONAHA.106.631549.
We would like to thank our technicians Kerstin Kretschel, Evelyn Polzin and Denise Kleindienst for their excellent assistance in acquiring the CMR images, Dr. Frank Beekmann for helping recruiting patients and performing echocardiographic examinations, and Dr. Victoria Claydon for careful editing of the manuscript. The study was supported by personal institutional research grants held by Professor Schulz-Menger.
The authors declare that they have no competing interests.
FKB, AR, RW and JSM have been involved in conception and design. FKB recruited the subjects. FKB, AR, RW, JSM have been involved in data acquisition. FKB, AR, RW and JSM analyzed the images. FKB and JSM analyzed and interpreted the data. FKB performed the statistical analysis. JSM supervised the study. FKB drafted the manuscript. JSM critically revised the manuscript and has given final approval of the version to be published. All authors had full access to the data and take responsibility for its integrity. All authors have read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
von Knobelsdorff-Brenkenhoff, F., Rudolph, A., Wassmuth, R. et al. Assessment of mitral bioprostheses using cardiovascular magnetic resonance. J Cardiovasc Magn Reson 12, 36 (2010). https://doi.org/10.1186/1532-429X-12-36
- Cardiovascular Magnetic Resonance
- Orifice Area
- Mitral Valve Area
- Pressure Half Time
- Mitral Prosthesis